Projects per year
Personal profile
Research interests
I am the leader of the theme ‘Tumor Immunology’ of the Cancer Center Amsterdam, a new research institute that combines the research programs of the 2 University Medical Centers in Amsterdam. After my PhD I set up a research group that performs both pre-clinical and translational studies with focus on (immune)biology and treatment of B-cell malignancies with CLL as main disease serving as a B-cell malignancy model. These studies were combined with both phase 1, 2 and 3 clinical trials for which he started an international network. These efforts have positioned the research group as the foremost clinical and translational CLL Center in the Netherlands and enabled me to build a large countrywide CLL biobank. As exemplified by a recent invited editorial in one of the leading medical journals in this field I am positioned as renowned international expert in this field (see ref. 2). See below a listed selection of achievements:
- Basic/translational research:
- Tumor microenvironment (TME): In vitro models simulating the tumor microenvironment of lymphnodes have been created within my group. This enabled pivotal studies which uncovered the important role of the TME in this disease which contributed to the development of novel targeted inhibitors. In vivo confirmation of this findings were established in an adapted CLL mouse model.
- Functional genetic studies: I have set up an European network to study the relevance of specific recurrent genetic aberrations in CLL, especially in relation to drug sensitivity. This work contributed to recognition of specific mutations such as TP53 that are now routinely tested to guide treatment decisions
- Adaptive immune responses: I have developed a track record of studies on the adaptive immune system in CLL. As T cells are a very small minority of total leukocytes in CLL (<5 to 1%), sophisticated methods have been set-up to facilitate such studies. These efforts made our group one of the main contributors to current knowledge on T cell dysfunction in CLL.
- Clinical research: When I took over the chairman position of the Dutch/Belgian HOVON CLL working group end of 2014, there were no open or planned trials. I reorganized the group, established an alliance with the Nordic CLL study group and (re)strengthened ties with other European study groups (especially the German CLL study group) and with pharma-industry. This has resulted in multiple international multicenter trials with novel agents in which my institute serves as central diagnostic and research laboratory for Netherlands and Belgium. Greatest achievement in this field has been the Hovon-associated global phase 3 MURANO study of which I am the principal investigator, which resulted in the establishment of a (practicing changing) new standard-of-care treatment for relapsed CLL patients.
External positions
President, Stichting Hovon Amsterdam, p/a VUmc
1 Jan 2023 → …
Board member, European School of Hematology
2021 → …
Board member, Wetenschappelijke raad Hematon
2021 → …
Chairman, EHA Scientific Working group of CLL
2020 → …
Chairman, HOVON CLL studygroup
1 Oct 2018 → …
Consultant / Advisor, Janssen, Abbvie, Roche/Genentech, BMS, Astra Zeneca, LAVA, Biogeneration, LINK
2018 → …
Board member, Eueropean Research Initiative of CLL
2017 → …
Keywords
- RC0254 Neoplasms. Tumors. Oncology (including Cancer)
- leukemia
- Immunology
Collaborations and top research areas from the last five years
-
Kater A.P.: development of, circumvention of and novel strategies for (development of) chemorefractory CLL
van Attekum, M., Brocco, F., van Bruggen, A., Hofland, T., Leeksma, A., de Weerdt, I., Kater, A. P., Slinger, E., Tonino, S. & Wensveen, F.
1/06/2012 → …
Project: Research
-
Eldering E.: Apoptosis regulation in immuno-hematology
Eldering, E., Kater, A. P., Slinger, E., Tonino, S., Wensveen, F., van der Windt, G., Derks, I., Terpstra, S., van Attekum, M., Brocco, F., Delgado, R., Hofland, T. & Leeksma, A.
1/01/2007 → …
Project: Research
-
van Oers M.H.J.: Pathogenesis and Immunotherapy of B cell malignancies
Gerritsen, M., Gillissen, M., Kroeze, A., Schimmel, M., Sins, J., van Tuijn, C., Biemond, B. J., Kater, A. P., Kersten, M. J., Zeerleder, S., Hazenberg, M., Slinger, E. & Tonino, S.
1/01/2006 → …
Project: Research
-
efficacy of plasma derived neutralizing antibodies in immunocompromized patients with COVID-19
Heijmans, J., Rijnders, B. & Kater, A. P.
Project: Research
-
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Thijssen, R., ter Burg, J., Garrick, B., van Bochove, G. G. W., Brown, J. R., Fernandes, S. M., Rodríguez, M. S., Michot, J-M., Hallek, M., Eichhorst, B., Reinhardt, H. C., Bendell, J., Derks, I. A. M., van Kampen, R. J. W., Hege, K., Kersten, M. J., Trowe, T., Filvaroff, E. H., Eldering, E. & Kater, A. P., 2016, In: Blood. 128, 4, p. 574-583Research output: Contribution to journal › Article › Academic › peer-review
62 Citations (Scopus) -
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
Thijssen, R., ter Burg, J., van Bochove, G. G. W., de Rooij, M. F. M., Kuil, A., Jansen, M. H., Kuijpers, T. W., Baars, J. W., Virone-Oddos, A., Spaargaren, M., Egile, C., van Oers, M. H. J., Eldering, E., Kersten, M. J. & Kater, A. P., 2016, In: Leukemia. 30, 2, p. 337-345Research output: Contribution to journal › Article › Academic › peer-review
17 Citations (Scopus) -
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification
te Raa, G. D., Moerland, P. D., Leeksma, A. C., Derks, I. A., Yigittop, H., Laddach, N., Loden-van Straaten, M., Navrkalova, V., Trbusek, M., Luijks, D. M., Zenz, T., Skowronska, A., Hoogendoorn, M., Stankovic, T., van Oers, M. H., Eldering, E. & Kater, A. P., 2015, In: Cell Death & Disease. 6, p. e1852Research output: Contribution to journal › Article › Academic › peer-review
11 Citations (Scopus) -
CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia
te Raa, G. D., Pascutti, M. F., García-Vallejo, J. J., Reinen, E., Remmerswaal, E. B. M., ten Berge, I. J. M., van Lier, R. A. W., Eldering, E., van Oers, M. H. J., Tonino, S. H. & Kater, A. P., 2014, In: Blood. 123, 5, p. 717-724Research output: Contribution to journal › Article › Academic › peer-review
54 Citations (Scopus) -
Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model
Lascano, V., Guadagnoli, M., Schot, J. G., Luijks, D. M., Guikema, J. E. J., Cameron, K., Hahne, M., Pals, S., Slinger, E., Kipps, T. J., van Oers, M. H. J., Eldering, E., Medema, J. P. & Kater, A. P., 2013, In: Blood. 122, 24, p. 3960-3963Research output: Contribution to journal › Article › Academic › peer-review
23 Citations (Scopus)